INTRODUCTION {#s1}
============

In China, esophageal cancer (EC) is the fourth most commonly diagnosed cancer in males and the fifth in females, with an estimated 477,900 new patients and 375,000 related deaths occurring in 2015 \[[@R1]\]. Esophageal squamous cell carcinoma (ESCC) is the main form of EC in China and Eastern Asia. The contributing risk factors for ESCC are not fully known, but are thought to involve low intake of vegetables and fruits, poor nutritional status, smoking and eating and/or drinking at high temperatures. However, these primarily identified risk factors could not account for all the etiology of ESCC. Nowadays, there are convincing evidences that obesity increases the susceptibility of many malignancies, including EC, postmenopausal breast cancer, endometrial cancer, colorectal cancer, pancreatic cancer and liver cancer \[[@R2]\]. A recent study indicated that preoperative metabolic syndrome might be an effective predictor of ESCC mortality \[[@R3]\]. These accumulating evidences suggested that obesity and diabetes related gene might play vital roles in the development of EC.

The *transcription factor 7-like 2* (*TCF7L2*) gene maps to the long arm of chromosome 10q25.3. TCF7L2 belongs to the high mobility group-box (HMGB) family \[[@R4]\] and is a versatile transcription factor. The TCF7L2 protein regulates Wnt/β-catenin signaling pathway \[[@R5]\], therefore it plays important roles in the development and growth of various cells \[[@R6], [@R7]\]. Ishiguro *et al.* reported that TCF7L2 expression was associated with a poor prognosis of ESCC \[[@R8]\]. A previous study suggested that *TCF7L2* rs7903146 locus might exert its enhancer function by interacting with HMGB1 \[[@R9]\]. *TCF7L2* single-nucleotide polymorphisms (SNPs) are proposed susceptibility factors for the development of cancer. Previous studies indicated that *TCF7L2* rs7903146 (C/T) polymorphism might influence the risk of breast cancer \[[@R10], [@R11]\]. *TCF7L2* rs290481 T\>C polymorphism located on near the 3' end of this gene. Ling *et al.* reported that this SNP was associated with hepatocellular carcinoma susceptibility with marginal significance \[[@R12]\]. However, the association between these *TCF7L2* SNPs and ESCC risk was not explored.

The *Leptin* (*LEP*) gene maps to chromosome 7q31.3. LEP is secreted by white adipose tissue and has been identified to be involved in endocrinologic metabolism \[[@R13]\]. It is thought that LEP may regulate the activation and serum levels of insulin. Thus, LEP may involve in the etiology of obesity \[[@R14]\], type 2 diabetes (T2DM) \[[@R15]\] and pathophysiology of carcinoma \[[@R16], [@R17]\]. LEP receptor (LEPR, also known as CD295) is a single transmembrane protein in human and distributes in various tissues \[[@R18]\]. LEP combines to LEPR and exerts its important roles in the development of metabolic disorders and malignancies. Several studies demonstrated that the elevated LEP levels might affect the onset and progression of many malignancies \[[@R19]--[@R22]\]. Thus, LEP and LEPR may be correlated with the development of ESCC. Results of meta-analyses found that both rs7799039 A\>G and rs2167270 G\>A polymorphisms in *LEP* gene might influence the risk of cancer \[[@R23]--[@R25]\]. In addition, a case-control study found that *LEP* rs2167270 G\>A was associated with the risk of esophageal adenocarcinoma \[[@R26]\]. There are several explanations for the function of these two *LEP* polymorphisms. It is suggested that rs7799039 A\>G polymorphism in the upstream region of LEP gene can affect leptin expression, possibly at the transcriptional level, thereby altering adipose secretion levels of the hormone \[[@R27]\]. Additionally, *LEP* rs2167270 G\>A is a 5'-utr SNP and may play regulatory roles in translation and stability of mRNA. LEPR rs1137100 G\>A, rs1137101 G\>A polymorphisms are missense SNPs and may alter the structure and the function of LEPR protein. Doecke *et al.* found *LEPR* rs1137100 G\>A, rs1137101 G\>A polymorphisms influence the risk of esophageal adenocarcinoma in Caucasians \[[@R26]\]. *LEPR* rs6588147 G\>A polymorphism locates on the intron region of LEPR gene. Slattery *et al.* found that *LEPR* rs6588147 G\>A polymorphism affected risk of colon cancer among men \[[@R28]\]. However, the association between *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms and ESCC risk remains unknown in Asians.

In this case-control study, we aimed to examine the potential association of *TCF7L2*, *LEP* and *LEPR* polymorphisms with the risk of ESCC in Eastern Chinese Han populations. The *TCF7L2* rs7903146 C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms were genotyped by SNPscan genotyping assays in 507 ESCC cases and 1,496 non-cancer controls.

RESULTS {#s2}
=======

Baseline characteristics {#s2_1}
------------------------

There were 2,003 participants in the present case-control study including 507 ESCC patients (377 males and 130 females) and 1,496 non-cancer controls (1,084 males and 412 females). The age and sex were well matched in two groups (P = 0.994, P = 0.406, respectively, Table [1](#T1){ref-type="table"}). The mean ± SD of weight and body mass index (BMI) was significantly higher in controls compared with ESCC patients (*P* \< 0.05). However, the mean ± SD of height was not significant (*P* \> 0.05). The proportion of smoking and drinking was significantly higher in ESCC patients compared with controls (*P* \< 0.05). Locus information of *TCF7L2*, *LEP* and *LEPR* polymorphisms is listed in Table [2](#T2){ref-type="table"}. The genotyping success rates for *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A SNPs were 99.50%,99.45%, 99.50%, 99.40%, 99.50%, 99.50% and 99.50%, respectively. Minor allele frequency (MAF) in controls is listed in Table [2](#T2){ref-type="table"}, which is very similar to the data of Chinese population. In addition, the distributions of the *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A genotypes in controls conform to Hardy-Weinberg equilibrium (HWE).

###### Distribution of selected demographic variables and risk factors in ESCC cases and controls

  Variable        Cases (n=507)   Controls (n=1, 496)   *P* ^a^                 
  --------------- --------------- --------------------- --------------- ------- ---------
  Age (years)     62.77 (±8.01)   62.77 (±8.84)         0.994                   
  Age (years)                                                                   0.225
   \< 63          271             53.45                 753             50.33   
   ≥ 63           236             46.55                 743             49.67   
  Sex                                                                           0.406
   Male           377             74.36                 1,084           72.46   
   Female         130             25.64                 412             27.54   
  Tobacco use                                                                   \<0.001
   Never          247             48.72                 1,090           72.86   
   Ever           260             51.28                 406             27.14   
  Alcohol use                                                                   \<0.001
   Never          341             67.26                 1,329           88.84   
   Ever           166             32.74                 167             11.16   
  Height (cm)     166.0 (±7.29)                         166.1 (±7.08)           0.743
  Weight (kg)     61.54 (±9.83)                         66.11 (±9.92)           \<0.001
  BMI (kg/m^2^)   22.27 (±2.90)                         23.91 (±3.03)           \<0.001
  BMI (kg/m^2^)                                                                 \<0.001
   \< 24          370                                   779                     
   ≥ 24           137                                   717                     

^a^ Two-sided *χ*^2^ test and student t test; Bold values are statistically significant (*P* \<0.05). BMI: body mass index.

###### Primary information for *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms

  Genotyped SNPs            Chromosome   Chr Pos (NCBI Build 37)   Region      MAF^a^ for Chinese in database   MAF in our controls (n = 1, 496)   *P* value for HWE^b^ test in our controls   Genotyping method   Genotyping value (%)
  ------------------------- ------------ ------------------------- ----------- -------------------------------- ---------------------------------- ------------------------------------------- ------------------- ----------------------
  *TCF7L2* rs7903146 C\>T   10           114758349                 Intron 4    0.026                            0.031                              0.733                                       SNPscan             99.50
  *TCF7L2* rs290481 T\>C    10           114923825                 Intron 13   0.405                            0.387                              0.097                                       SNPscan             99.45
  *LEP* rs7799039 A\>G      7            127878783                 Promoter    0.201                            0.266                              0.543                                       SNPscan             99.50
  *LEP* rs2167270 G\>A      7            127881349                 5' UTR      0.175                            0.222                              0.324                                       SNPscan             99.40
  *LEPR* rs1137100 G\>A     1            66036441                  Exon 4      0.169                            0.160                              0.316                                       SNPscan             99.50
  *LEPR* rs1137101 G\>A     1            66058513                  Exon 6      0.111                            0.122                              0.763                                       SNPscan             99.50
  *LEPR* rs6588147 G\>A     1            65935494                  Intron 2    0.150                            0.150                              0.260                                       SNPscan             99.50

^a^ MAF: minor allele frequency.

^b^ HWE: Hardy--Weinberg equilibrium.

Association of TCF7L2 rs7903146C\>T, rs290481 T\>C, LEP rs7799039 A\>G, rs2167270 G\>A and LEPR rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms with ESCC risk {#s2_2}
------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

The genotype distributions of *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms are listed in Table [3](#T3){ref-type="table"}. In the analysis of *LEPR* rs6588147 G\>A polymorphism, we found significant differences in the distribution of the rs6588147 AA genotype compared with the rs6588147 GG genotype and rs6588147 AA genotype compared with the rs6588147 GA/GG genotypes between 507 ESCC cases and 1,496 controls \[AA vs. GG: crude odds ratio (OR) = 1.87, 95% confidence interval (CI) = 1.02--3.43, *P* = 0.042 and AA vs. GG/GA: crude OR = 1.93, 95% CI = 1.06--3.53, *P* = 0.031 (Table [3](#T3){ref-type="table"})\]. Results of multivariate linear regression analysis indicated that *LEPR* rs6588147 G\>A polymorphism increased the risk of ESCC. When the *LEPR* rs6588147 GG/GA genotypes were used as the reference group, the *LEPR* rs6588147 AA genotype was associated with the increased risk of ESCC \[AA vs. GG/GA: adjusted OR = 1.90, 95% CI = 1.00--3.61, *P* = 0.049 (Table [3](#T3){ref-type="table"})\]. However, we found that *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A polymorphisms were not associated with the development of overall ESCC (Table [3](#T3){ref-type="table"}).

###### Logistic regression analyses of association between *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms and risk of ESCC

  Genotype                 ESCC cases (n=507)   Controls (n=1, 496)   Crude OR (95%CI)   *P*     Adjusted OR ^a^ (95%CI)   *P*                               
  ------------------------ -------------------- --------------------- ------------------ ------- ------------------------- ----------- --------------------- -----------
  *TCF7L2* rs7903146C\>T                                                                                                                                     
  CC                       475                  94.25                 1,399              93.96   1.00                                                        
  CT                       29                   5.75                  89                 5.98    0.96(0.62-1.48)           0.847       1.03(0.65-1.62)       0.908
  TT                       0                    0                     1                  0.07    \-                        \-          \-                    \-
  CT+TT                    29                   5.75                  90                 6.04    0.95(0.62-1.46)           0.814       1.01(0.64-1.60)       0.954
  CC+CT                    504                  100.00                1488               99.93   1.00                                  1.00                  
  TT                       0                    0                     1                  0.07    \-                        \-          \-                    \-
  T allele                 29                   2.88                  91                 3.06                                                                
  *TCF7L2* rs290481 T\>C                                                                                                                                     
  TT                       195                  38.77                 575                38.62   1.00                                                        
  TC                       228                  45.33                 676                45.40   0.99(0.79-1.23)           0.903       0.96(0.76-1.22)       0.748
  CC                       80                   15.90                 238                15.98   0.98(0.73-1.33)           0.911       0.99(0.71-1.36)       0.927
  TC+CC                    308                  61.23                 914                61.38   0.99(0.81-1.22)           0.952       0.98(0.78-1.22)       0.830
  TT+TC                    423                  84.10                 1,251              84.02   1.00                                  1.00                  
  CC                       80                   15.90                 238                15.98   0.99(0.75-1.31)           0.967       1.01(0.75-1.36)       0.949
  C allele                 388                  38.57                 1,152              38.68                                                               
  *LEP* rs7799039 A\>G                                                                                                                                       
  AA                       291                  57.74                 797                53.53   1.00                                  1.00                  
  AG                       184                  36.51                 591                39.69   0.85(0.69-1.05)           0.138       0.85(0.67-1.06)       0.144
  GG                       29                   5.75                  101                6.78    0.79(0.51-1.21)           0.275       0.73(0.46-1.17)       0.191
  AG+GG                    213                  42.26                 692                46.47   0.84(0.69-1.03)           0.101       0.83(0.67-1.03)       0.091
  AA+AG                    475                  94.25                 1,388              93.22   1.00                                  1.00                  
  GG                       29                   5.75                  101                6.78    0.84(0.55-1.28)           0.419       0.79(0.50-1.24)       0.300
  G allele                 242                  24.01                 793                26.63                                                               
  *LEP* rs2167270 G\>A                                                                                                                                       
  GG                       318                  63.35                 894                60.04   1.00                                  1.00                  
  GA                       165                  32.87                 528                35.46   0.87(0.70-1.08)           0.213       0.87(0.69-1.09)       0.220
  AA                       19                   3.78                  67                 4.50    0.79(0.47-1.34)           0.382       0.81(0.47-1.42)       0.469
  GA+AA                    184                  36.65                 595                39.96   0.87(0.71-1.07)           0.190       0.86(0.69-1.08)       0.198
  GG+GA                    483                  96.22                 1,422              95.50   1.00                                  1.00                  
  AA                       19                   3.78                  67                 4.50    0.84(0.50-1.40)           0.496       0.86(0.49-1.50)       0.591
  A allele                 203                  20.22                 662                22.23                                                               
  *LEPR* rs1137100 G\>A                                                                                                                                      
  GG                       342                  67.86                 1,045              70.18   1.00                                  1.00                  
  GA                       147                  29.17                 411                27.60   1.09(0.87-1.37)           0.448       1.08(0.85-1.38)       0.517
  AA                       15                   2.98                  33                 2.22    1.39(0.74-2.58)           0.304       1.30(0.67-2.52)       0.436
  GA+AA                    162                  32.14                 444                29.82   1.12(0.90-1.39)           0.327       1.10(0.87-1.39)       0.417
  GG+GA                    489                  97.02                 1,456              97.78   1.00                                  1.00                  
  AA                       15                   2.98                  33                 2.22    1.35(0.73-2.51)           0.338       1.27(0.66-2.46)       0.472
  A allele                 177                  17.56                 477                16.02                                                               
  *LEPR* rs1137101 G\>A                                                                                                                                      
  GG                       390                  77.38                 1,146              76.96   1.00                                  1.00                  
  GA                       108                  21.43                 322                21.63   0.98(0.77-1.26)           0.898       0.91(0.70-1.18)       0.473
  AA                       6                    1.19                  21                 1.41    0.84(0.34-2.09)           0.705       0.91(0.35-2.37)       0.848
  GA+AA                    114                  22.62                 343                23.04   0.98(0.77-1.24)           0.848       0.91(0.70-1.18)       0.468
  GG+GA                    498                  98.81                 1,468              98.59   1.00                                  1.00                  
  AA                       6                    1.19                  21                 1.41    0.84(0.34-2.10)           0.712       0.93(0.36-2.42)       0.884
  A allele                 120                  11.90                 364                12.22                                                               
  *LEPR* rs6588147 G\>A                                                                                                                                      
  GG                       367                  72.82                 1,070              71.86   1.00                                  1.00                  
  GA                       119                  23.61                 391                26.26   0.89(0.70-1.12)           0.316       0.85(0.66-1.09)       0.199
  AA                       18                   3.57                  28                 1.88    **1.87(1.02-3.43)**       **0.042**   1.82(0.96-3.46)       0.068
  GA + AA                  137                  27.18                 419                28.14   0.95(0.76-1.20)           0.680       0.91(0.72-1.16)       0.465
  GG+GA                    486                  96.43                 1,461              98.12   1.00                                  1.00                  
  AA                       18                   3.57                  28                 1.88    **1.93(1.06-3.53)**       **0.031**   **1.90(1.00-3.61)**   **0.049**
  A allele                 155                  15.38                 447                15.01                                                               

^a^ Adjusted for age, sex, BMI, alcohol use and smoking status.

Bold values are statistically significant (*P* \<0.05).

Association of TCF7L2 rs7903146C\>T, rs290481 T\>C, LEP rs7799039 A\>G, rs2167270 G\>A and LEPR rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms with ESCC risk in Different Stratification Groups {#s2_3}
-----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

Table [4](#T4){ref-type="table"} shows the genotype frequencies of *LEP* rs7799039 A\>G polymorphism in the subgroup analyses. In ≥63 years subgroup, after adjustment for gender, smoking status, BMI and alcohol use, the *LEP* rs7799039 GG genotype decreased ESCC risk compared with the *LEP* rs7799039 AA genotype genotype or *LEP* rs7799039 AA/AG \[GG vs. AA: adjusted OR = 0.47, 95% CI 0.23--0.95, *P* = 0.035 and GG vs. AA/AG: adjusted OR = 0.48, 95% CI = 0.24--0.96, *P* = 0.038 (Table [4](#T4){ref-type="table"})\]. In BMI ≥ 24 kg/m^2^ subgroup, after adjustment for age, gender, smoking status and alcohol use, we found that *LEP* rs7799039 AG genotype decreased the risk of ESCC \[AG vs. AA: adjusted OR = 0.66, 95% CI 0.45--0.99, *P* = 0.044 (Table [4](#T4){ref-type="table"})\].

###### Stratified analyses between *LEP* rs7799039 A\>G polymorphism and ESCC risk by sex, age, BMI, smoking status and alcohol consumption

  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *LEP* rs7799039 A\>G (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                       
  --------------------- ---------------------------------------- ------------------------------ ------- ------ ----------------------- ----------------------- -------------------- ------------------------
  Sex                                                                                                                                                                               

  Male                  222/581                                  134/425                        19/72   1.00   0.81(0.62-1.06);\       0.60(0.33-1.06);\       0.77(0.60-1.00);\    0.65(0.37-1.15);\
                                                                                                               *P*: 0.117              *P*: 0.079              *P*: 0.052           *P*: 0.136

  Female                69/216                                   50/166                         10/29   1.00   0.97(0.63-1.50);\       1.324 (0.60-2.97);\     1.03(0.68-1.55);\    1.36 (0.62-2.95);\
                                                                                                               *P*: 0.901              *P*: 0.475              *P*: 0.897           *P*: 0.442

  Age                                                                                                                                                                               

  \<63                  139/395                                  79/306                         18/46   1.00   0.78(0.56-1.11);\       1.31 (0.69-2.50);\      0.84(0.60-1.16);\    1.43 (0.76-2.69);\
                                                                                                               *P*: 0.166              *P*: 0.409              *P*: 0.282           *P*: 0.263

  ≥63                   152/402                                  105/285                        11/55   1.00   0.95(0.70-1.29);\       **0.47(0.23-0.95);**\   0.88 (0.65-1.18);\   **0.48 (0.24-0.96);**\
                                                                                                               *P*: 0.737              ***P*: 0.035**          *P*: 0.395           ***P*: 0.038**

  Smoking status                                                                                                                                                                    

  Never                 146/589                                  83/427                         16/70   1.00   0.79(0.59-1.08);\       0.99(0.55-1.78);\       0.83(0.62-1.10);\    1.09(0.61-1.93);\
                                                                                                               *P*: 0.135              *P*: 0.970              *P*: 0.190           *P*: 0.779

  Ever                  145/208                                  101/164                        13/31   1.00   0.92(0.65-1.31);\       0.49(0.23-1.02);\       0.84(0.60-1.18);\    0.50(0.24-1.04);\
                                                                                                               *P*: 0.637              *P*: 0.057              *P*: 0.306           *P*: 0.063

  Alcohol consumption                                                                                                                                                               

  Never                 198/706                                  122/526                        18/91   1.00   0.82(0.63-1.06);\       0.72(0.42-1.23);\       0.81 (0.63-1.04);\   0.78(0.46-1.33);\
                                                                                                               *P*: 0.135              *P*: 0.229              *P*: 0.097           *P*: 0.359

  Ever                  93/91                                    62/65                          11/10   1.00   1.06(0.64-1.77);\       0.75(0.28-1.96);\       0.99(0.61-1.60);\    0.72(0.28-1.85);\
                                                                                                               *P*: 0.820              *P*: 0.552              *P*: 0.955           *P*: 0.492

  BMI (kg/m^2^)                                                                                                                                                                     

  \<24                  210/436                                  137/285                        20/53   1.00   0.96(0.72-1.26);\       0.63(0.35-1.13);\       0.90 (0.69-1.18);\   0.64(0.36-1.13);\
                                                                                                               *P*: 0.744              *P*: 0.118              *P*: 0.458           *P*: 0.126

  ≥24                   81/361                                   47/306                         9/48    1.00   **0.66(0.45-0.99);**\   0.93(0.43-1.99);\       0.69(0.48-1.01);\    1.09(0.52-2.31);\
                                                                                                               ***P*: 0.044**          *P*: 0.847              *P*: 0.058           *P*: 0.816
  ----------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ For *LEP* rs7799039 A\>G, the genotyping was successful in 507 (99.41%) ESCC cases, and 1,496 (99.53%) controls.

^b^ Adjusted for multiple comparisons \[age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly)\] in a logistic regression model.

The genotype frequencies of *LEPR* rs1137101 G\>A polymorphism in the subgroup analyses are showed in Table [5](#T5){ref-type="table"}. In ever smoking subgroup, after adjustment for gender, age, BMI and alcohol use, the *LEPR* rs1137101 GA genotype was associated with the decreased risk of ESCC \[GA vs. GG: adjusted OR = 0.66, 95% CI 0.44--1.00, *P* = 0.049 (Table [5](#T5){ref-type="table"})\]. In ever drinking subgroup, after adjustment for gender, smoking status, BMI and age, we found that *LEPR* rs1137101 GA and GA/AA genotypes decreased the risk of ESCC \[GA vs. GG: adjusted OR = 0.54, 95% CI 0.31--0.95, *P* = 0.031 and GA/AA vs. GG: adjusted OR = 0.54, 95% CI 0.31--0.93, *P* = 0.027 (Table [5](#T5){ref-type="table"})\].

###### Stratified analyses between *LEPR* rs1137101 G\>A polymorphism and ESCC risk by sex, age, BMI, smoking status and alcohol consumption

  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *LEPR* rs1137101 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                      
  --------------------- ----------------------------------------- ------------------------------ ------ ------ ----------------------- -------------------- ----------------------- --------------------
  Sex                                                                                                                                                                               

  Male                  292/832                                   78/235                         5/11   1.00   0.84(0.61-1.15);\       1.52(0.49-4.75);\    0.87(0.64-1.18);\       1.57(0.50-4.91);\
                                                                                                               *P*: 0.275              *P*: 0.473           *P*: 0.353              *P*: 0.435

  Female                98/314                                    30/87                          1/10   1.00   1.11(0.68-1.81);\       0.27(0.03-2.24);\    1.02(0.63-1.65);\       0.27 (0.03-2.20);\
                                                                                                               *P*: 0.686              *P*: 0.226           *P*: 0.943              *P*: 0.220

  Age                                                                                                                                                                               

  \<63                  177/579                                   55/157                         4/11   1.00   1.06 (0.72-1.57);\      1.77 (0.51-6.13);\   1.09(0.74-1.59);\       1.73(0.50-5.98);\
                                                                                                               *P*: 0.772              *P*: 0.370           *P*: 0.666              *P*: 0.387

  ≥63                   213/567                                   53/165                         2/10   1.00   0.75(0.52-1.08);\       0.43(0.09-2.02);\    0.74(0.52-1.06);\       0.46(0.10-2.16);\
                                                                                                               *P*: 0.123              *P*: 0.283           *P*: 0.097              *P*: 0.323

  Smoking status                                                                                                                                                                    

  Never                 186/848                                   56/221                         3/17   1.00   1.15(0.82-1.61);\       0.72(0.20-2.56);\    1.12(0.80-1.57);\       0.70(0.20-2.49);\
                                                                                                               *P*: 0.432              *P*: 0.613           *P*: 0.504              *P*: 0.585

  Ever                  204/298                                   52/101                         3/4    1.00   **0.66(0.44-1.00);**\   1.51(0.30-7.58);\    0.68(0.46-1.02);\       1.65 (0.33-8.24);\
                                                                                                               ***P*: 0.049**          *P*: 0.616           *P*: 0.063              *P*: 0.543

  Alcohol consumption                                                                                                                                                               

  Never                 260/1,028                                 73/276                         5/19   1.00   1.00(0.74-1.35);\       1.04(0.37-2.89);\    1.01(0.75-1.35);\       1.04(0.38-2.89);\
                                                                                                               *P*: 0.999              *P*: 0.943           *P*: 0.953              *P*: 0.939

  Ever                  130/118                                   35/46                          1/2    1.00   **0.54(0.31-0.95);**\   0.56(0.04-8.70);\    **0.54(0.31-0.93);**\   0.64(0.04-9.68);\
                                                                                                               ***P*: 0.031**          *P*: 0.679           ***P*: 0.027**          *P*: 0.750

  BMI (kg/m^2^)                                                                                                                                                                     

  \<24                  279/600                                   83/165                         5/9    1.00   0.99(0.72-1.36);\       1.32(0.42-4.18);\    1.01(0.74-1.38);\       1.33(0.42-4.20);\
                                                                                                               *P*: 0.930              *P*: 0.633           *P*: 0.972              *P*: 0.623

  ≥24                   111/546                                   25/157                         1/12   1.00   0.76(0.47-1.22);\       0.39(0.05-3.12);\    0.73(0.45-1.16);\       0.41(0.05-3.29);\
                                                                                                               *P*: 0.250              *P*: 0.376           *P*: 0.183              *P*: 0.405
  ------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ For *LEPR* rs1137101 G\>A, the genotyping was successful in 507 (99.41%) ESCC cases, and 1,496 (99.53%) controls.

^b^ Adjusted for multiple comparisons \[age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly)\] in a logistic regression model.

Table [6](#T6){ref-type="table"} shows the genotype frequencies of *LEPR* rs6588147 G\>A polymorphism in the subgroup analyses. In \<63 years subgroup, after adjustment for gender, smoking status, BMI and alcohol use, the *LEPR* rs6588147 AA genotype increased ESCC risk compared with the *LEPR* rs6588147 GG and GA/GG genotypes \[AA vs. GG: adjusted OR = 2.58, 95% CI 1.00--6.62, *P* = 0.049 and AA vs. GA/GG: adjusted OR = 2.71, 95% CI 1.06--6.91, *P* = 0.038 (Table [6](#T6){ref-type="table"})\]. In male subgroup, after adjustment for age, smoking status, BMI and alcohol use, the *LEPR* rs6588147 AA genotype was associated with the increased risk of ESCC \[AA vs. GG: adjusted OR = 2.19, 95% CI 1.02--4.67, *P* = 0.044 and AA vs. GA/GG: adjusted OR = 2.26, 95% CI 1.06--4.80, *P* = 0.035 (Table [6](#T6){ref-type="table"})\]. However, in ever drinking subgroup, after adjustment for age, gender, smoking status and BMI, the *LEPR* rs6588147 GA genotype decreased the risk of ESCC \[GA vs. GG: adjusted OR = 0.54, 95% CI 0.31--0.92, *P* = 0.024 (Table [6](#T6){ref-type="table"})\].

###### Stratified analyses between *LEPR* rs6588147 G\>A polymorphism and ESCC risk by sex, age, BMI, smoking status and alcohol consumption

  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------
  Variable              *LEPR* rs6588147 G\>A (case/control)^a^   Adjusted OR^b^ (95% CI); *P*                                                                                      
  --------------------- ----------------------------------------- ------------------------------ ------- ------ ----------------------- ----------------------- ------------------- -----------------------
  Sex                                                                                                                                                                               

  Male                  267/769                                   94/290                         14/19   1.00   0.89(0.67-1.20);\       **2.19(1.02-4.67);**\   0.97(0.73-1.29);\   **2.26(1.06-4.80);**\
                                                                                                                *P*: 0.449              ***P*: 0.044**          *P*: 0.834          ***P*: 0.035**

  Female                100/301                                   25/101                         4/9     1.00   0.72(0.43-1.20);\       1.19(0.34-4.22);\       0.76(0.47-1.24);\   1.29(0.37-4.55);\
                                                                                                                *P*: 0.204              *P*: 0.785              *P*: 0.274          *P*: 0.688

  Age                                                                                                                                                                               

  \<63                  168/527                                   59/206                         9/14    1.00   0.80(0.55-1.16);\       **2.58(1.00-6.62);**\   0.88(0.62-1.26);\   **2.71(1.06-6.91);**\
                                                                                                                *P*: 0.233              ***P*: 0.049**          *P*: 0.484          ***P*: 0.038**

  ≥63                   199/543                                   60/185                         9/14    1.00   0.84(0.59-1.20);\       1.40(0.58-3.39);\       0.90(0.64-1.26);\   1.48(0.61-3.56);\
                                                                                                                *P*: 0.339              *P*: 0.458              *P*: 0.534          *P*: 0.386

  Smoking status                                                                                                                                                                    

  Never                 180/787                                   56/279                         9/20    1.00   0.89(0.63-1.24);\       1.88(0.82-4.31);\       0.96(0.70-1.32);\   1.94(0.85-4.44);\
                                                                                                                *P*: 0.486              *P*: 0.139              *P*: 0.807          *P*: 0.117

  Ever                  187/283                                   63/112                         9/8     1.00   0.80(0.54-1.17);\       2.00(0.71-5.66);\       0.86(0.59-1.25);\   2.12 (0.75-5.97);\
                                                                                                                *P*: 0.248              *P*: 0.191              *P*: 0.438          *P*: 0.155

  Alcohol consumption                                                                                                                                                               

  Never                 245/961                                   80/335                         13/27   1.00   0.92(0.69-1.23);\       1.69(0.84-3.40);\       0.99(0.75-1.30);\   1.73(0.86-3.47);\
                                                                                                                *P*: 0.590              *P*: 0.145              *P*: 0.944          *P*: 0.124

  Ever                  122/109                                   39/56                          5/1     1.00   **0.54(0.31-0.92);**\   5.03(0.48-52.46);\      0.60(0.35-1.01);\   5.79(0.56-59.52);\
                                                                                                                ***P*: 0.024**          *P*: 0.177              *P*: 0.056          *P*: 0.139

  BMI (kg/m^2^)                                                                                                                                                                     

  \<24                  261/552                                   92/204                         14/18   1.00   0.94(0.69-1.28);\       1.79(0.84-3.82);\       1.01(0.76-1.36);\   1.83(0.86-3.89);\
                                                                                                                *P*: 0.700              *P*: 0.130              *P*: 0.936          *P*: 0.115

  ≥24                   106/518                                   27/187                         4/10    1.00   0.67(0.42-1.07);\       1.96(0.59-6.59);\       0.73(0.47-1.14);\   2.14(0.64-7.17);\
                                                                                                                *P*: 0.093              *P*: 0.275              *P*: 0.168          *P*: 0.215
  ---------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------------

^a^ For *LEPR* rs1137101 G\>A, the genotyping was successful in 507 (99.41%) ESCC cases, and 1,496 (99.53%) controls.

^b^ Adjusted for multiple comparisons \[age, sex, BMI, smoking status and alcohol consumption (besides stratified factors accordingly)\] in a logistic regression model.

In addition, after a logistic regression analysis, we found that *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs2167270 G\>A and *LEPR* rs1137100 G\>A polymorphisms were not associated with the risk of ESCC in any subgroup (data not shown).

DISCUSSION {#s3}
==========

The pathogenesis of ESCC was very complex. Multiple factors (e.g. a number of genetic and environmental factors) may contribute to the etiology of ESCC. Understanding of the individual's heredity background may be helpful for the prevention and treatment of ESCC. In this study, we selected energy metabolism and insulin-sensibility relative gene (*TCF7L2*, *LEP* and *LEPR*) polymorphisms and focused on their susceptibility to ESCC. The association between *LEPR* rs6588147 G\>A polymorphism and the increased risk of overall ESCC was identified. We also found that *LEPR* rs6588147 G\>A polymorphism increased the risk of ESCC in \<63 years and male subgroups. *LEP* rs7799039 A\>G was associated with the risk of ESCC in ≥63 years and BMI ≥ 24 kg/m^2^ subgroups. In addition, *LEPR* rs1137101 G\>A polymorphism decreased the risk of ESCC in ever smoking and ever drinking subgroups.

There was a difference in the *LEPR* rs6588147 G\>A polymorphism between overall ESCC patients and non-cancer controls. The *LEPR* rs6588147 AA genotype were higher in ESCC patients compared with controls, indicating that *LEPR* rs6588147 AA genotype may contribute to esophageal carcinogenesis. The *LEPR* rs6588147 G\>A polymorphism is located on intron of *LEPR* gene. It may be difficult to interpret the exact function of intronic polymorphism. However, the possible interpretations may be as follows. The intronic polymorphism rs6588147 G\>A is located near the regulatory components or splice acceptor site, where any slight variant may lead to the disruption of the splice site and induce aberrant splicing \[[@R29]\]. This SNP probably influences the expression of the LEPR protein by altering mRNA splicing. However, we found that *LEPR* rs6588147 AA genotype may decrease the risk of ESCC in ever drinking subgroup. These findings seemed to be controversial. The probable reason might be due to the limited sample size in this subgroup, which could generate an unauthentic results.

LEP is mainly secreted by adipose tissue, and has been suggested to promote tumor growth \[[@R30]\]. Some studies indicated that the serum LEP level was significantly higher in breast cancer patients compared with which in controls both pre-menopausal and post-menopausal \[[@R31], [@R32]\]. A number of studies have found that LEP may play vital roles in cell proliferation, apoptosis, cell migration and angiogenesis \[[@R33], [@R34]\]. Results of several meta-analyses suggested that *LEP* rs7799039 G allele might decrease the risk of multiple cancers \[[@R24], [@R25], [@R35]--[@R37]\]. However, there was only one study focused on the relationship between *LEP* rs7799039 A\>G polymorphism and cancer risk in Asian populations. Thus, the association of this polymorphism with cancer risk might be unclear in Asians. In this study, we conducted a case-control study focused on the association between *LEP* rs7799039 A\>G polymorphism and ESCC risk with a relatively large sample size. We found *LEP* rs7799039 A\>G was associated with the decreased risk of ESCC in ≥63 years and BMI ≥ 24 kg/m^2^ subgroups. These findings were very similar to the results of previous studies. Hoffsted *et al.* reported that individuals carried the *LEP* rs7799039 AA genotype had higher serum LEP levels than those who carried the *LEP* rs7799039AG or GG genotypes \[[@R27]\]. In this study, we found that *LEP* rs7799039 A\>G polymorphism was a protective factor for ESCC, suggesting the presence of the *LEP* rs7799039 G allele, which is associated with the decreased level of LEP, might decrease the risk of ESCC.

Several case-control study focused on the relationship of *LEPR* rs1137101 G\>A polymorphism and the risk of cancer. Recently, results of two meta-analyses indicated that this SNP was not associated with the risk of overall cancer \[[@R37], [@R38]\]. In addition, most of these studies conducted on Caucasian population. The evidence of the association between *LEPR* rs1137101 G\>A polymorphism and cancer risk was insufficient in Asians. A previous study suggested that *LEPR* rs1137101 G\>A polymorphism might be associated with variation in binding with LEP and, as such, inter-individual differences in serum LEP levels \[[@R39]\]. Just as we mentioned above, LEP may affect cell proliferation, apoptosis, cell migration and angiogenesis. *LEPR* rs1137101 G\>A polymorphism may alter the susceptibility of cancer by influencing the ability of binding with LEP. Thus, we aimed to examine the potential association of this polymorphism with the risk of ESCC in Eastern Chinese Han subjects. We found that the *LEPR* rs1137101 G\>A polymorphism decreased ESCC risk in ever drinking and ever smoking subgroups. In the future, function of *LEPR* rs1137101 G\>A polymorphism should be further explored to confirm these primary findings in ESCC.

Our study had several limitations. Firstly, ESCC patients and controls were enrolled from two hospitals of Jiangsu University and Fujian Medical University and might therefore not be full-representative of the general Eastern Chinese Han population; the possible bias might lead to spurious findings. Secondly, for the limited ESCC patients recruited in this study, this study might have insufficient power to observe the potential relationships. Thirdly, because we only selected some functional polymorphisms in *TCF7L2*, *LEP* and *LEPR* gene, a fine-mapping case-control studies should be conducted in the future. Finally, for lack of some important risk factors, the interactive effect between gene-gene and gene-environment was not further analyzed.

In summary, our findings suggest that *LEPR* rs6588147 G\>A polymorphism is associated with the increased risk of ESCC in Eastern Chinese Han population. However, the results of this case-control study highlight that *LEP* rs7799039 A\>G and *LEPR* rs1137101 G\>A polymorphisms may decrease the risk of ESCC. A fine-mapping study with large sample size and functional exploration is needed to confirm our findings.

MATERIALS AND METHODS {#s4}
=====================

Subjects {#s4_1}
--------

A total number of 507 ESCC patients and 1,496 non-cancer controls were enrolled in this study. The ESCC patients were from the Affiliated People's Hospital, Jiangsu University and the Affiliated Union Hospital, Fujian Medical University between August 2013 and December 2016. The diagnosis of ESCC was confirmed based on pathological examination. At the same time, the controls were recruited from physical examination center in these hospitals with sex and age matched. Each subject signed an informed written consent. This study was approved by the Institutional Review Board of Jiangsu University and Fujian Medical University for human subjects (No. SQ20140030, K201408, respectively). When each subject was interviewed, a questionnaire was used to obtain demographic variables and risk factors. And weight and height were also measured. In this study, a BMI ≥ 24 was considered as the criteria for obesity and overweight \[[@R40], [@R41]\].

DNA extraction and genotyping {#s4_2}
-----------------------------

Genomic DNA was carefully isolated from EDTA-anticoagulated blood of recipients by using a Promega DNA blood mini kit (Promega, Madison, USA). *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A genotypes were assessed by the SNPscan™ kit (Gnensky Biotechologies Inc., Shanghai, China), which is a double ligation and multiplex fluorescence PCR \[[@R42]\]. For quality control, eighty DNA samples (4%) were randomly selected and genotyped by different colleague. The genotypes of *TCF7L2*, *LEP* and *LEPR* polymorphisms were confirmed.

Statistical analysis {#s4_3}
--------------------

Continuous variables (e.g. age, height, weight and BMI) are expressed as mean ±standard deviation (SD). Comparisons between ESCC patients and controls were carried out with Student's t-test. The categorical variables (e.g. *TCF7L2*, *LEP* and *LEPR* genotypes, sex, age, BMI, smoking and drinking status) were compared with Chi-square test (*χ*^2^). Deviations from the HWE for *TCF7L2*, *LEP* and *LEPR* genotypes distribution in controls were evaluated by an internet-based calculator (<http://ihg.gsf.de/cgi-bin/hw/hwa1.pl>) \[[@R43]--[@R49]\]. The relationships of *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms with ESCC susceptibility were evaluated by crude ORs and 95% CIs. Multivariate linear regression adjusted for age, sex, BMI, alcohol use and smoking status was used to determine the relationships between *TCF7L2* rs7903146C\>T, rs290481 T\>C, *LEP* rs7799039 A\>G, rs2167270 G\>A and *LEPR* rs1137100 G\>A, rs1137101 G\>A and rs6588147 G\>A polymorphisms and ESCC risk with quantitative traits. Data analysis was conducted with SAS software for windows (Version 9.4, SAS Institute, Cary, NC). A *P* \< 0.05 (two-tailed) was accepted as the criterion of statistical significance.
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